Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06341231
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2024-03-12
Brief Title:
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
Sponsor:
Xiangya Hospital of Central South University
Organization:
Xiangya Hospital of Central South University
Study Overview
Official Title:
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism in Specific Populations With Older Age Renal Insufficiency or Co-existing Malignancy
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this prospective observational study is to explore the influencing factors of the efficacy and safety of anticoagulant therapy for pulmonary thromboembolism in special populations with older age renal insufficiency or co-existing malignancy and establish a predictive model to guide clinical practice The main questions it aims to answer are
To analyze the influencing factors of the efficacy and safety of anticoagulant therapy for specific populations with pulmonary thromboembolism PTE in the real world such as the elderly those with impaired kidney function and individuals with malignant tumors
Whether we can use machine-learning models to predict bleeding events and VTE recurrence in special populations following anticoagulant therapy in the real world Participants will receive diagnostic and therapeutic measures for pulmonary thromboembolism in accordance with clinical guidelines including anticoagulant therapy Some patients need to have peripheral blood samples collected at the time of enrollment and 3 months after anticoagulant therapy
To analyze the influencing factors of the efficacy and safety of anticoagulant therapy for specific populations with pulmonary thromboembolism PTE in the real world such as the elderly those with impaired kidney function and individuals with malignant tumors
Whether we can use machine-learning models to predict bleeding events and VTE recurrence in special populations following anticoagulant therapy in the real world Participants will receive diagnostic and therapeutic measures for pulmonary thromboembolism in accordance with clinical guidelines including anticoagulant therapy Some patients need to have peripheral blood samples collected at the time of enrollment and 3 months after anticoagulant therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None